ersonal use only
AGM
NOVEMBER 2021
----------------
ASX: ANR
Developing the next generation of gastrointestinal health
onlyproducts
• More than ever, the world is looking for safe and effective solutions for gastrointestinal tract (GIT or 'gut') symptoms and disorders
•
use• •
The Anatara team is focused on delivering evidence-based treatments and solutions for gastrointestinal health needs in humans and animals
ersonal• Anatara aims to assist the homeostasis of the "gut" to promote overall health and wellbeing
• Commencing clinical trials in FY22, with fast potential speed to market
• Strong pre-clinical data for Inflammatory Bowel Disease (IBD)
1. https://nutraceuticalbusinessreview.com/news/article_page/A_good_gut_feeling_why_digestive_health_is_the_next_wellness_frontier/177171
Achievements
only | Human health assets | |
Achievements | ||
• All components GRAS (FDA: generally regarded as | ||
safe) | ||
• Patent pending formulation with functional | ||
use | coatings of synergistic combination of components | |
• Achieved clinical trial ethics approvals: GaRP and | ||
3FDC | ||
• GMP clinical batches manufactured and released | ||
ersonal | for clinical trial | |
• Clinical trial - Irritable Bowel Syndrome | ||
• Commenced August 2021 | ||
• Clinical trial - Psychological Functioning | ||
• Commencing late November 2021 | ||
Animal health assets
Achievements
- Detach® patents granted in Australia and Japan
- Developed new bromelain-based formulations to offer convenient delivery options (in-feed, in- water) and for new species (poultry, aquaculture)
- ANR-pf:challenge trial in poultry for subclinical and necrotic enteritis successfully completed
- BONIFF + Ridley's SMEC: Challenge trial in piglets for enterotoxigenic Escherichia coli completed
Program pipeline
only | PRECLINICAL | CLINICAL | COMMERCIAL | ||||||||
PROGRAM | DELIVERY DISCOVERY | REGISTRATION | |||||||||
In-Vivo | Proof of | RIGHTS | |||||||||
In-Vitro | Pivotal | ||||||||||
(animal) | Concept | ||||||||||
Irritable Bowel Syndrome (Diarrhoea) | |||||||||||
GaRP | 18-65 | Oral | ✓ | ✓ | ✓ | Mar '22 | Sep '22 | Global | |||
Minitabs | |||||||||||
HUMAN | |||||||||||
use | Moderate Depression, Anxiety or Stress | ||||||||||
3FDC | 15-55 | Oral | ✓ | ✓ | ✓* | Apr '22 | Global | ||||
Minitabs | |||||||||||
Scour (diarrhoea) | |||||||||||
Detach® | Piglets | Oral | ✓ | ✓ | ✓ | ✓ | ✓ | Australia (APVMA) | Global | ||
Drench | |||||||||||
ersonal | |||||||||||
ANIMAL | BONIFF | Piglets | Oral | ✓ | ✓ | ✓ | ✓ | Global | |||
In-feed | |||||||||||
Subclinical & Clinical Necrotic Enteritis | |||||||||||
ANR-pf | Chicks | Oral | ✓ | ✓ | ✓ | ✓ | Global | ||||
In-water | |||||||||||
* Third party published studies on individual components of 3FDC
Building a Health Portfolio
• | Anatara aims to be the 'go to' company for gut health solutions, |
including treatments, diagnostics and advice | |
only | |
• | Focused on delivering evidence-based treatments and solutions for GIT |
health needs
GaRP Technology to provide a pipeline of products
• Potential to apply our GaRP technology into other GIT conditions, IBD
in particular, and several largely unaddressed paediatric indications | |
use | |
• | 3FDC is a combination of some components of GaRP used specifically |
for psycho-emotional indications
Presently evaluating diagnostics and other GIT therapeutic opportunities
ersonal | |
• | To offer consumers and patients broader solutions to GIT complaints |
• To diversify Anatara's portfolio of GIT health solutions | |
• | We anticipate initiating one of these opportunities in the next 6 |
months |
This is an excerpt of the original content. To continue reading it, access the original document here.